SSA
BIO icon

Schonfeld Strategic Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,000
Closed -$1.61M – 2074
2023
Q4 		$1.61M Buy
+5,000
New +$1.57M 0.01% 873

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Schonfeld Strategic Advisors's BIO Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 1,971 shares — an estimated $597K sold.

Schonfeld Strategic Advisors first reported a position in BIO in Q1 2016 and held it in 34 quarters. The position peaked at $152M in Q2 2022. 392 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,971 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $597K.
  • Schonfeld Strategic Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2016 and held it in 34 quarters.
  • Schonfeld Strategic Advisors's Bio-Rad Laboratories Class A position peaked at $152M in Q2 2022.
  • 392 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.